Iambic Raises $150M in an AI Drug Discovery IPO

TL;DR: Iambic Therapeutics, a San Diego AI drug discovery company, raised $150 million in its IPO, per BioPharma Dive, selling about 9.4 million shares at $16 each. It trades on Nasdaq as IAM from October 15. Most of the money funds cancer drug trials, not the AI.

When I look at an IPO, I start with how the early investors lose before I look at how they win. I signed off on QA work in the Navy only after it was verified, and I read IPO numbers the same way. Iambic is a clean case, because the cap table says more than the first-day price will, and the filings are public for anyone willing to read them before the stock starts moving.

How did the IPO price?

It priced at $16 a share. The company's own pricing announcement gives 9,375,000 shares at $16.00 and $150.0 million in gross proceeds, with the offering expected to close October 16, 2026.

Underwriters also hold a 30-day option, per the company, to buy up to 1,406,250 more shares at the same price. Fierce Biotech estimates that option could add about $22.5 million if it is fully used.

What happens to early investors in an IPO?

They get diluted. Every new share sold to the public shrinks the percentage that existing holders own. If you invest in venture funds or angel syndicates, that is the ordinary arithmetic of an IPO. Your percentage shrinks even when the company does well. The exact stake changes for Iambic's largest holders are in the company's S-1 on SEC EDGAR, and I'd read them there before relying on any summary.

Where does the money go?

Most of it goes to drug trials. Here is how Fierce Biotech reports Iambic plans to spend it. An inhibitor, in the table, is a drug that blocks one specific protein.

Use of proceeds	Amount	What it funds
IAM1363	$75 million	An inhibitor aimed at HER2, a protein behind some breast and lung tumors; phase 1 study, then phase 2 and phase 3
IAM217	$15 million	Taking an inhibitor of a protein called KIF18A into the clinic, aimed at ovarian and triple-negative breast cancer
IAM-C1	$15 million	A phase 1 study of a drug that blocks two proteins, CDK2 and CDK4, aimed at breast cancers
AI platform	$20 million	Training new versions of its Enchant and NeuralPLexer models

That is $105 million for clinical programs and $20 million for the platform. This is a cancer drug developer that uses AI, and trial results will decide how it is judged. Iambic had $207.9 million in the bank at the end of June, and Fierce reports the company previously said the IPO would fund its plans through the end of 2028.

What does the company actually have?

Its first drug is IAM1363, developed for HER2-positive solid tumors. BioPharma Dive says early Phase 1 data showed "clinical anti-tumor activity" and an encouraging safety profile in patients who had tried and failed multiple lines of treatment. That is early human data from a small group of patients with few options left, and it is not proof the drug works.

The company is still spending heavily on trials. Its half-year loss and revenue figures are in the S-1 on SEC EDGAR, and I'd take them from there.

Is the valuation cheap or rich?

It depends on which comparison you pick. A Yahoo Finance analysis noted that on the day Iambic launched its roadshow, Bloomberg reported Isomorphic Labs was in early talks to raise at a valuation of at least $40 billion. Iambic names Isomorphic as a competitor. Against that, a company raising $150 million in an IPO sits in a very different weight class.

Against a company whose lead drug is in early human testing, the IPO price may look fine. Public markets will give a daily answer. The first trial readouts will give a better one, and they are what will decide whether the $16 price looks cheap or rich a year from now.

What does this mean if you invest in private markets?

It shows the path from private round to public price. Private investors had put in $462 million since 2019, per BioPharma Dive, before the public market set its own price at $16 a share. Whether any early investor did well depends on their entry price, and the sources don't give those prices.

If you want the mechanics of getting into companies before they list, I covered that in pre-IPO investing through Forge and EquityZen and compared the two main marketplaces in EquityZen vs. Hiive. For how exits change with SEC rule shifts, see the semi-annual reporting rule and IPO exits. For a different way to approach late-stage companies, read why mid-cap pre-IPO plays win.

Common mistakes when reading an IPO like this

The first is treating "AI" in the description as the business. Here the biggest line item is a cancer drug in early trials, and a failed trial hurts the stock no matter how good the models are.

The second is reading the raise as proof of quality. A completed raise tells you demand existed on one day. It doesn't tell you the science works.

The third is ignoring the burn rate. Iambic is spending cash on trials, and Fierce Biotech reports the company expects the IPO to fund its plans only through the end of 2028. Read the prospectus for what happens after that.

FAQ

What are some good AI drug discovery stocks? I don't pick stocks, and Angel Investors Network doesn't recommend securities. Iambic (Nasdaq: IAM) is the AI drug discovery company in this story. Before forming a view on any of them, read the filings for the trial pipeline and cash runway.

Which AI stock is the latest to IPO? Iambic is a very recent one. Per the company, its stock is expected to begin trading on October 15, 2026, under IAM. It raised $150 million at $16 a share.

How much did Iambic's IPO raise, and what is it for? It raised $150.0 million gross, per the company. Per Fierce Biotech, $75 million goes to its lead HER2 drug, $15 million each to two other cancer programs, and $20 million to its AI platform.

What are the top AI drug discovery companies? Iambic, now public, and Isomorphic Labs, which Iambic names as a competitor, are two. Isomorphic is private and led by Google DeepMind co-founder Demis Hassabis, per Yahoo Finance.

What to do next

Sign up for the free AIN briefing at angelinvestorsnetwork.com and I'll send you the next IPO or exit with the dilution and downside worked out first.

Educational content only. Not investment, tax, or legal advice. Not an offer or solicitation to buy or sell securities. Past performance does not guarantee future results. Private-market investments are illiquid and involve risk of loss, including total loss of capital. Consult qualified advisers. Angel Investors Network is not a broker-dealer or investment adviser.